Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Wagatsuma, Kohei; Yokoyama, Yoshihiro; Nakase, Hiroshi

doi:10.3390/life11121375

Cited by 26 publications

(26 citation statements)

References 166 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among other inflammatory markers, FCP has proven to be the best biomarker for monitoring mucosal response to IFX therapy [ 53 , 54 , 55 ]. In our study we found that, although patients had high levels of ATIs, FCP decreased over the course of infusions.…”

Section: Discussionmentioning

confidence: 99%

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients

Pesole

Liso

Donghia

et al. 2023

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and Ulcerative Colitis (UC), are multifactorial disorders characterized by a chronic inflammatory status with the secretion of cytokines and immune mediators. Biologic drugs targeting pro-inflammatory cytokines, such as infliximab, are broadly used in the treatment of IBD patients, but some patients lose responsiveness after an initial success. The research into new biomarkers is crucial for advancing personalized therapies and monitoring the response to biologics. The aim of this single center, observational study is to analyze the relationship between serum levels of 90K/Mac-2 BP and the response to infliximab, in a cohort of 48 IBD patients (30 CD and 18 UC), enrolled from February 2017 to December 2018. In our IBD cohort, high 90K serum levels were found at baseline in patients who then developed anti-infliximab antibodies at the fifth infusion (22 weeks after the first), becoming non-responders (9.76 ± 4.65 µg/mL compared to 6.53 ± 3.29 µg/mL in responder patients, p = 0.005). This difference was significant in the total cohort and in CD, but not significant in UC. We then analyzed the relationship between serum levels of 90K, C-reactive protein (CRP), and Fecal calprotectin. A significant positive correlation was found at baseline between 90K and CRP, the most common serum inflammation marker (R = 0.42, p = 0.0032). We concluded that circulating 90K could be considered a new non-invasive biomarker for monitoring the response to infliximab. Furthermore, 90K serum level determination, before the first infliximab infusion, in association with other inflammatory markers such as CRP, could assist in the choice of biologics for the treatment of IBD patients, thereby obviating the need for a drug switch due to loss of response, and so improving clinical practice and patient care.

show abstract

Section: Discussionmentioning

confidence: 99%

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients

Pesole

Liso

Donghia

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Mucosal healing is an important therapeutic goal in the management of UC, and biomarkers for the evaluation of mucosal healing have been widely used in clinical practice [ 26 ]. Endoscopic severity has been reported to predict the prognosis of UC, and the achievement of mucosal healing has been recognized to be important [ 2 , 3 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study

et al. 2022

View full text Add to dashboard Cite

Background Biomarkers such as fecal calprotectin (FC) and fecal immunochemical occult blood tests (FIT) for ulcerative colitis (UC) are used in clinical practice. In this study, the effect of UC disease duration on FC was investigated and compared to that on FIT. Methods One hundred twenty-eight colonoscopic examinations and two fecal biomarkers measurements were performed. The cases of UC were divided into short- and long-term disease-duration groups or categorized into three groups with disease durations of 0–5, 6–13, and 14–38 years. We analyzed correlations between biomarker levels and endoscopic scores, including the Mayo endoscopic subscore (MES), ulcerative colitis endoscopic index of severity, and the sum of MES. Results In the analysis of short- and long-term disease durations, the three endoscopic scores and biomarker levels showed significant correlations in both long-term and short-term groups. Most of the correlation coefficients for the individual long-term group were lower than the corresponding values for all cases, while most of the correlation coefficients for the individual short-term groups were higher than the corresponding values for all cases. In the three-group analysis (disease durations of 0–5, 6–13, and 14–38 years), the two biomarkers and three endoscopic scores showed significant correlations, and most of the correlation coefficients between biomarkers and endoscopic scores tended to be lower in the long-term follow-up group. In the receiver operating characteristic analysis for predicting mucosal healing in the three groups, the area under the curve for FC and FIT concentrations in the 0–5 year disease-duration group showed particularly higher values than those for the other two groups. Conclusions Similar to FIT, FC is affected by the duration of UC, indicating that FC may be a highly useful biomarker, especially in short-term disease.

show abstract

“… 12 , 13 Moreover, recurrent hospitalizations in patients with COVID‐19 and frailty in elderly or diabetic patients during COVID‐19 infection are suggested to be also related to increased inflammatory burden. 14 , 15 , 16 The biomarkers that involved in the immune‐inflammatory and coagulation pathways, such as CRP, NLR, D‐D, have been used to assess the disease severity and prognosis of multiple chronic, inflammatory or autoimmune diseases, such as irritable bowel disease, 17 diabetes mellitus, 18 and Hashimoto's disease. 19 Therefore, accurate monitoring of inflammatory factors plays an important role in the judgment of disease progression and the selection of treatment strategies for COVID‐19 patients.…”

Section: Introductionmentioning

confidence: 99%

Serum biomarker panel for disease severity and prognosis in patients with COVID‐19

Tang

Liu

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Coronavirus disease‐2019 (COVID‐19) has become a worldwide emergency and has had a severe impact on human health. Inflammatory factors have the potential to either enhance the efficiency of host immune responses or damage the host organs with immune overreaction in COVID‐19. Therefore, there is an urgent need to investigate the functions of inflammatory factors and serum markers that participate in disease progression. Methods In total, 54 COVID‐19 patients were enrolled in this study. Disease severity was evaluated by clinical evaluation, laboratory tests, and computed tomography (CT) scans. Data were collected at: admission, 3–5 days after admission, when severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA detection became negative, and composite endpoint. Results We found that the positive rate in sputum was three times higher than that in throat swabs. Higher levels of C‐reactive protein (CRP), lactate dehydrogenase (LDH), D‐dimer (D‐D), interleukin‐6 (IL‐6) and neutrophil‐to‐lymphocyte ratio (NLR) or lower lymphocyte counts suggested more severe disease, and the levels of cytokines and serum markers were intrinsically correlated with disease progression. When SARS‐CoV‐2 RNA detection became negative, the receiver operating characteristic (ROC) curve demonstrated that LDH had the highest sensitivity independently, and four indicators (NLR, CRP, LDH, and D‐D) when combined had the highest sensitivity in distinguishing critically ill patients from mild ones. Conclusions Monitoring dynamic changes in NLR, CRP, LDH, IL‐6, and D‐D levels, combined with CT imaging and viral RNA detection in sputum, could aid in severity evaluation and prognosis prediction and facilitate COVID‐19 treatment.

show abstract

Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Cited by 26 publications

References 166 publications

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients

Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study

Serum biomarker panel for disease severity and prognosis in patients with COVID‐19

Contact Info

Product

Resources

About